Administration is mostly associated with fever. Occasionally, patients experience a flu-like syndrome consisting of fever, chills, bone pain and/or arthralgia and myalgia.
Gastrointestinal reactions eg, nausea/vomiting and anorexia, have been reported following administration. Injection site reactions eg, erythema, redness or swelling were observed infrequently and resolved in most cases without treatment within 24-48 hrs.
Azotemia has been reported during therapy with zoledronic acid; serum creatinine should be monitored. Electrolyte imbalances may occur during treatment with zoledronic acid.
Hypocalcemia, hypomagnesemia and hypophosphatemia have been reported. Monitor serum calcium, phosphate and magnesium during therapy; short-term supplementation of these electrolytes may be necessary.
View ADR Monitoring Form